Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)

Adaptimmune is a biotechnology company focused on developing T-cell therapy to treat cancer

The company specializes in harnessing the power of the immune system, particularly using engineered T-cell receptors (TCRs), to target and eliminate cancer cells more effectively. Adaptimmune’s innovative approach aims to improve patient outcomes in various cancers by personalizing therapies to the individual’s unique tumor characteristics. Through ongoing research and clinical trials, the company strives to bring transformative treatment options to patients suffering from life-threatening malignancies.